European Patent Convention

SciSparc Secures Strategic Advantage with Grant of European Patent

Retrieved on: 
Venerdì, Maggio 31, 2024
European Patent Convention, Intellectual property, Disorder, Patent, Research, World Health Organization, TEL, Cannabinoid, Central nervous system, Pharmaceutical industry

This is in addition to the patent titled “Compositions and Methods of Potentiating Antimicrobials” previously granted by the United States Patent and Trademark Office.

Key Points: 
  • This is in addition to the patent titled “Compositions and Methods of Potentiating Antimicrobials” previously granted by the United States Patent and Trademark Office.
  • This patent grant bolsters the Company's intellectual property portfolio, extending the protection of its global patent holdings.
  • This grant not only reinforces SciSparc’s position in a key market, but also enhances its competitive edge in the global pharmaceutical landscape.
  • The patent describes the pharmaceutical compositions and methods for potentiating various antimicrobials and minimizing their side-effects.

Medigene AG Expands its End-to-End Platform by Submitting Three Development Optimization Technology Patents to the European Patent Office

Retrieved on: 
Martedì, Maggio 28, 2024
European Patent Convention, Patent, Safety, TCR, Interferon, Pharmaceutical industry

The first patent submission covers the Company's innovative Interferon-gamma (IFNγ) Biosensor, a technology that enables real-time monitoring and quantification of IFNγ release from cytokine-secreting cells.

Key Points: 
  • The first patent submission covers the Company's innovative Interferon-gamma (IFNγ) Biosensor, a technology that enables real-time monitoring and quantification of IFNγ release from cytokine-secreting cells.
  • Additionally, Medigene has filed two patents for its novel T cell receptor (TCR)-specific Antigen-Antibody combination technology, UniTope & TraCR.
  • “These innovative tools enable Medigene to increase the overall efficiency for the development of potential best-in-class TCRs and TCR-based therapies.
  • Medigene continually extends and strengthens its patent portfolio with new technologies and expands existing patents into additional jurisdictions.

Faron Founders and bexmarilimab Developers Selected as Finalists for the European Inventor Award 2024

Retrieved on: 
Giovedì, Maggio 16, 2024
Faron Pharmaceuticals, Patient, MDS, European Patent Convention, Myelocyte, AIM, European, SME, Invention, Research, Macrophage, Myelodysplastic syndrome, Majesty of the Seas, Nasdaq First North, Immunotherapy, Standard of care, Quality of life, SOC, Pharmaceutical industry

Dr. Markku Jalkanen, co-founder, Board member and former CEO of Faron, and Dr. Sirpa Jalkanen, co-founder and member of Faron’s Scientific Advisory Board, have been nominated in recognition of their research developing Faron’s wholly owned precision cancer immunotherapy candidate, bexmarilimab.

Key Points: 
  • Dr. Markku Jalkanen, co-founder, Board member and former CEO of Faron, and Dr. Sirpa Jalkanen, co-founder and member of Faron’s Scientific Advisory Board, have been nominated in recognition of their research developing Faron’s wholly owned precision cancer immunotherapy candidate, bexmarilimab.
  • In addition, every year, the public can vote for their favorite inventor: the Popular Prize goes to the shortlisted inventor with the most votes.
  • The winners in each category, and the winner of the Popular Prize, will be announced at the online award ceremony on 9 July 2024.
  • The continued progress of our ambitious bexmarilimab development program and the exceptional data we are seeing in the ongoing Phase I/II BEXMAB trial, reaffirms our belief in the potential of bexmarilimab to change the treatment paradigm.

Bioxodes receives European Patent Office intention to grant patent, offering lead asset broad protection in thromboinflammation

Retrieved on: 
Giovedì, Maggio 16, 2024
Patient, European Patent Convention, Intellectual property, Hope, Thrombosis, Patent, Stroke, Intracerebral hemorrhage, Bleeding, Inflammation, Saliva, Neutrophil, Pharmaceutical industry

“The European Patent Office's intention to grant a patent for BIOX-101 in Europe represents a significant milestone for the advancement of this first-in-class drug, offering a breakthrough hope for hemorrhagic stroke patients, and demonstrating potential applicability across related conditions.

Key Points: 
  • “The European Patent Office's intention to grant a patent for BIOX-101 in Europe represents a significant milestone for the advancement of this first-in-class drug, offering a breakthrough hope for hemorrhagic stroke patients, and demonstrating potential applicability across related conditions.
  • The European Patent Office plays a leading role in how patent decisions are taken across the world, and we anticipate favorable outcomes for our patent filings in other countries as well,” said Marc Dechamps, Chief Executive Officer of Bioxodes.
  • BIOX-101 has enjoyed patent protection in the US and Europe for several years for its active ingredient and for the treatment of thrombosis.
  • The active ingredient in BIOX-101 is derived from a protein found in tick saliva, effectively preventing blood clot formation without increasing bleeding risks.

Court Revokes Two Advanced Cell Diagnostics Patents, Dismisses Infringement Claims Against Molecular Instruments and Orders Advanced Cell Diagnostics to Make Payment of £1.35 Million to Molecular Instruments

Retrieved on: 
Martedì, Maggio 21, 2024
Professional Services, Health, Technology, Legal, Nanotechnology, Health Technology, Biotechnology, High court, Judgement, Bio-Techne, European Patent Convention, Patents Court, Research

Molecular Instruments, Inc. announced that the Patents Court of the High Court of England and Wales has ordered: (1) that two patents owned by Advanced Cell Diagnostics, Inc. (a Bio-Techne group company; NASDAQ: TECH) both be revoked; (2) that Advanced Cell Diagnostics’ infringement claims against Molecular Instruments are dismissed; and (3) that Advanced Cell Diagnostics make a costs payment of £1.35 million (approximately $1.72 million at the current exchange rate) to Molecular Instruments.

Key Points: 
  • Molecular Instruments, Inc. announced that the Patents Court of the High Court of England and Wales has ordered: (1) that two patents owned by Advanced Cell Diagnostics, Inc. (a Bio-Techne group company; NASDAQ: TECH) both be revoked; (2) that Advanced Cell Diagnostics’ infringement claims against Molecular Instruments are dismissed; and (3) that Advanced Cell Diagnostics make a costs payment of £1.35 million (approximately $1.72 million at the current exchange rate) to Molecular Instruments.
  • In a 2022 lawsuit filed at the High Court of England and Wales (proceedings no.
  • HP-2022-000026), Advanced Cell Diagnostics alleged that Molecular Instruments’ HCR™ RNA-ISH technology infringed European Patents (UK) 2,500,439 and 1,910,572.
  • “We are pleased that the UK matter is now concluded,” said Dr. Harry Choi, CEO of Molecular Instruments.

ASLAN Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

Retrieved on: 
Giovedì, Maggio 9, 2024
Chicago Medical School, Sale, University, Patient, Rutgers University, ATS, Alopecia areata, Kinetics, Skin, European Patent Convention, Research, MD, Doctor of Philosophy, Conference, KOL, Potential, ADS, Week, Patent, Data, Dupilumab, University of Rochester, Translational medicine, International Examiner, Magnetic resonance, Atopic dermatitis, Harvard Medical School, ASLN, TREK, Clutch (eggs), Interim, Biology, American Thoracic Society, Associate, Emergency medicine, EPO, SAN, COPD, Pharmaceutical industry

SAN MATEO, Calif. and SINGAPORE, May 09, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced financial results for the first quarter ended March 31, 2024, and provided an update on recent corporate activities.

Key Points: 
  • SAN MATEO, Calif. and SINGAPORE, May 09, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced financial results for the first quarter ended March 31, 2024, and provided an update on recent corporate activities.
  • Research and development expenses were $5.9 million for the first quarter of 2024 compared to $14.1 million for the first quarter of 2023.
  • General and administrative expenses were $3.4 million for the first quarter of 2024 compared to $4.0 million for the first quarter of 2023.
  • Net loss attributable to stockholders for the first quarter of 2024 was $9.9 million compared to a net loss of $19.1 million for the first quarter of 2023.

Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

Retrieved on: 
Giovedì, Maggio 9, 2024
Mortality, FDA, Research and development, TEL, Systemic scleroderma, Nature, Capital, Publication, CMMB, Primary sclerosing cholangitis, European Patent Convention, Research, Communication, Proteomics, Digestate, MD, Doctor of Philosophy, Liver, UPMC, Administration, PSC, Disease, Therapy, Patent, Risk, Patient, Scleroderma, Diagnosis, Biomarker, Clinical trial, CCL24, UC, Pharmaceutical industry

TEL AVIV, Israel, May 09, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq:CMMB), (Chemomab), a clinical-stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced financial and operating results for the first quarter ended March 31, 2024, and provided a corporate update.

Key Points: 
  • (Nasdaq:CMMB), (Chemomab), a clinical-stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced financial and operating results for the first quarter ended March 31, 2024, and provided a corporate update.
  • In January, 2024, Chemomab reported publication of new proteomics research in the peer-reviewed journal Cells reinforcing the clinical potential of CM-101 in primary sclerosing cholangitis.
  • Research and Development (R&D) Expenses: R&D expenses were $3.1 million for the first quarter of 2024, compared to $6.9 million for the first quarter of 2023.
  • General and Administrative (G&A) Expenses: G&A expenses were $0.9 million for the first quarter of 2024, compared to $2.2 million for the first quarter of 2023.

ProQR Announces First Quarter 2024 Operating and Financial Results

Retrieved on: 
Giovedì, Maggio 9, 2024
EON, Trident, Annual general meeting, Research, Partnership, Doctor of Philosophy, Webcast, Biomarker, Knowledge, Cholestasis, NTCP, RNA editing, Oncology, European Patent Convention, Oligonucleotide, Serum, Lilly, Eli Lilly and Company, Ribose, Pseudouridine, Poster, Alnylam Pharmaceuticals, Eli Lilly, RNA, Exercise, NHP, Clinical trial, ProQR, ADAR, B4GALT1, Adenosine, EDT, Science, Patent, Patient, Liver, Eon, Metabolism, Uridine, Q&A, Pharmaceutical industry

(Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today reported its financial and operating results for the first quarter ended March 31, 2024, and provided a business update.

Key Points: 
  • (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today reported its financial and operating results for the first quarter ended March 31, 2024, and provided a business update.
  • At March 31, 2024, ProQR held cash and cash equivalents and short term financial assets of €102.7 million, compared to €118.9 million cash and cash equivalents at December 31, 2023.
  • General and administrative costs were €3.5 million for the quarter ended March 31, 2024 compared to €4.0 million for the same period last year.
  • For further financial information for the period ended March 31, 2024, please refer to the Q1 financial report filing.

ORYZON Reports Financial Results and Corporate Update for Quarter Ended March 31, 2024

Retrieved on: 
Lunedì, Maggio 6, 2024
Charcot–Marie–Tooth disease, FDA, Venetoclax, OHSU, Innovation, National Cancer Institute, BPD, Development, IND, CNS, NET, Schizophrenia, EVOLUTION, JHU, Azacitidine, NCI, FCCC, Deficit spending, IP, Paclitaxel, IIS, Food, European Patent Convention, CMT, Borderline personality disorder, Communication, Conference, AML, Aggression, Convertible bond, FMS, ALS, Phase, Kabuki syndrome, HOPE, Safety, SCLC, DSM-IV codes, EMA, Clinical trial, Medicine, EPO, Investigational New Drug, Duration, Platinum, Bangladesh Technical Education Board, Phase II, MRD, ICIS, MSKCC, Disease, Measure (mathematics), CRADA, Dor, Patent, HDAC6, Data analysis, Genomics, Pharmaceutical industry

Dr Carlos Buesa, Oryzon’s Chief Executive Officer, said: “Oryzon continued with a strong path in its clinical programs in the first quarter.

Key Points: 
  • Dr Carlos Buesa, Oryzon’s Chief Executive Officer, said: “Oryzon continued with a strong path in its clinical programs in the first quarter.
  • Research and development (R&D) expenses were $2.6 million for the quarter ended March 31, 2024, compared to $4.4 million for the quarter ended March 31, 2023.
  • General and administrative expenses were $0.9 million for the quarter ended March 31, 2024, compared to $1.2 million for the quarter ended March 31, 2023.
  • Net losses were $1.1 for the quarter ended March 31, 2024, respectively, compared to $1.4 million for the quarter ended March 31, 2023.

Can-Fite Received Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602

Retrieved on: 
Lunedì, Maggio 6, 2024
Professional Services, Oncology, Patent Law, Health, Pharmaceutical, Biotechnology, Use, IP, European Patent Convention, Diabetes, A3, Erectile dysfunction, ICM, Patent, Patient, Vardenafil, Inflammation, Sildenafil, Tadalafil, ED, CANF, PDE5, Pharmaceutical industry

Can-Fite recently published an article in Andrologia , suggesting that CF602 could potentially offer an alternative to the current drugs on market.

Key Points: 
  • Can-Fite recently published an article in Andrologia , suggesting that CF602 could potentially offer an alternative to the current drugs on market.
  • A full erectile recovery was achieved following a single dose of CF602 with restored muscle collagen ratio and endothelial cell function.
  • “This additional European patent for erectile dysfunction adds to our growing IP estate for this high-value indication of the CF602 drug candidate.
  • The Erectile Dysfunction market is expected to reach approximately $6.6 billion by 2030, according to Market Research Future.